April 27, 2020 / 8:32 PM / a month ago

BRIEF-Moderna Announces Ind Submitted To U.S. FDA For Phase 2 Study Of Mrna Vaccine (Mrna-1273) Against Novel Coronavirus

April 27 (Reuters) - Moderna Inc:

* MODERNA ANNOUNCES IND SUBMITTED TO U.S. FDA FOR PHASE 2 STUDY OF MRNA VACCINE (MRNA-1273) AGAINST NOVEL CORONAVIRUS

* MODERNA INC - 600 PARTICIPANT PHASE 2 STUDY TO BEGIN UPON IND ACCEPTANCE AND SAFETY DATA FROM ONGOING NIH-LED PHASE 1 STUDY

* MODERNA INC - PLANNING UNDERWAY FOR PHASE 3 STUDY; STUDY EXPECTED TO BEGIN IN FALL OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below